ASCO 2020 | FIH study of CX-2029 in patients with advanced cancer

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, highlights results from the PROCLAIM-CX-2029 study (NCT03543813). This first in human study evaluated CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor) in patients with advanced cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).